Ethics

What does the bankruptcy of CARD, the largest autism treatment company in the U.S., have to teach us about the role of private equity in health care?

The leading U.S. therapy for autism is no panacea and has shown mixed results. Critics say it’s time to look for alternatives—and consult people with autism.

Proto.life interviews law professor and ethicist Nita Farahany and techno-humanist Aza Raskin at the BrainMind Summit.

How should medical AI be regulated, and who is responsible when deadly mistakes occur?

Longevity startups are riding high as a wave of gene therapies advance through clinical trials. Can they actually turn back the clock?

Autism is highly heritable—but is it a disease? Should it be cured? Could screening for it lead to eugenics? We explore the complicated landscape.

Oregon’s grand experiment in training psychedelic facilitators is facing a tangle of ambiguity and red tape.

Researchers have designed a light-activated genetic kill switch to prevent male chicks from hatching, since they have no economic value.

A book about shamanic journeys in the backyard and another about the dietary wisdom of roaming herbivores.

A new technique for same sex conception for men raises some tricky questions.